{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:35:51Z","timestamp":1791394551833,"version":"4.3.3"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:00:00Z","timestamp":1722038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:00:00Z","timestamp":1722038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s11864-024-01249-6","type":"journal-article","created":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T05:01:25Z","timestamp":1722056485000},"page":"1063-1072","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Systemic Management of Advanced Adrenocortical Carcinoma"],"prefix":"10.1007","volume":"25","author":[{"given":"Jeffery S.","family":"Russell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,27]]},"reference":[{"issue":"8","key":"1249_CR1","doi-asserted-by":"publisher","first-page":"636","DOI":"10.14740\/jocmr3503w","volume":"10","author":"E Sharma","year":"2018","unstructured":"Sharma E, et al. The characteristics and trends in adrenocortical carcinoma: A United States population based study. J Clin Med Res. 2018;10(8):636\u201340. https:\/\/doi.org\/10.14740\/jocmr3503w.","journal-title":"J Clin Med Res."},{"issue":"5","key":"1249_CR2","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s00268-005-0329-x","volume":"30","author":"E Kebebew","year":"2006","unstructured":"Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg. 2006;30(5):872\u20138. https:\/\/doi.org\/10.1007\/s00268-005-0329-x.","journal-title":"World J Surg"},{"issue":"16","key":"1249_CR3","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.3390\/cancers14163904","volume":"14","author":"I Tizianel","year":"2022","unstructured":"Tizianel I, et al. The overall survival and progression-free survival in patients with advanced adrenocortical cancer is increased after the multidisciplinary team evaluation. Cancers (Basel). 2022;14(16):3904. https:\/\/doi.org\/10.3390\/cancers14163904.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"1249_CR4","doi-asserted-by":"publisher","first-page":"R90","DOI":"10.1530\/EO-22-0050","volume":"2","author":"R Al-Ward","year":"2022","unstructured":"Al-Ward R, Zsembery C, Habra MA. Adjuvant therapy in adrenocortical carcinoma: prognostic factors and treatment options. Endocr Oncol. 2022;2(1):R90\u2013101. https:\/\/doi.org\/10.1530\/EO-22-0050.","journal-title":"Endocr Oncol"},{"issue":"3","key":"1249_CR5","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.asjsur.2012.08.008","volume":"36","author":"C Rangel","year":"2013","unstructured":"Rangel C, Scattolin G, Pais-Costa SR, Vieira E, Gaio E. Neoadjuvant chemotherapy and salvage surgery for an aldosterone-producing adrenal carcinoma with inferior vena cava thrombus: case report and literature review. Asian J Surg. 2013;36(3):134\u20136. https:\/\/doi.org\/10.1016\/j.asjsur.2012.08.008.","journal-title":"Asian J Surg"},{"issue":"4","key":"1249_CR6","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.athoracsur.2011.05.013","volume":"92","author":"CD Kemp","year":"2011","unstructured":"Kemp CD, et al. Pulmonary resection for metastatic adrenocortical carcinoma: the National Cancer Institute experience. Ann Thorac Surg. 2011;92(4):1195\u2013200. https:\/\/doi.org\/10.1016\/j.athoracsur.2011.05.013.","journal-title":"Ann Thorac Surg"},{"issue":"6","key":"1249_CR7","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1007\/s00268-014-2484-4","volume":"38","author":"BK Bednarski","year":"2014","unstructured":"Bednarski BK, et al. Borderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy. World J Surg. 2014;38(6):1318\u201327. https:\/\/doi.org\/10.1007\/s00268-014-2484-4.","journal-title":"World J Surg"},{"issue":"1","key":"1249_CR8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1245\/s10434-014-3944-7","volume":"22","author":"BM Dy","year":"2015","unstructured":"Dy BM, et al. Surgical resection of synchronously metastatic adrenocortical cancer. Ann Surg Oncol. 2015;22(1):146\u201351. https:\/\/doi.org\/10.1245\/s10434-014-3944-7.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1249_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s40001-023-01381-3","volume":"28","author":"Y Lin","year":"2023","unstructured":"Lin Y, et al. Pediatric adrenocortical carcinoma: clinical features and application of neoadjuvant chemotherapy. Eur J Med Res. 2023;28(1):411. https:\/\/doi.org\/10.1186\/s40001-023-01381-3.","journal-title":"Eur J Med Res."},{"issue":"23","key":"1249_CR10","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1056\/NEJMoa063360","volume":"356","author":"M Terzolo","year":"2007","unstructured":"Terzolo M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356(23):2372\u201380. https:\/\/doi.org\/10.1056\/NEJMoa063360.","journal-title":"N Engl J Med"},{"issue":"4","key":"1249_CR11","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jamcollsurg.2015.12.013","volume":"222","author":"LM Postlewait","year":"2016","unstructured":"Postlewait LM, et al. Outcomes of adjuvant mitotane after resection of adrenocortical carcinoma: A 13-Institution atudy by the US adrenocortical carcinoma group. J Am Coll Surg. 2016;222(4):480\u201390. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2015.12.013.","journal-title":"J Am Coll Surg"},{"key":"1249_CR12","doi-asserted-by":"publisher","first-page":"9362108","DOI":"10.1155\/2018\/9362108","volume":"2018","author":"Y Tang","year":"2018","unstructured":"Tang Y, Liu Z, Zou Z, Liang J, Lu Y, Zhu Y. Benefits of adjuvant mitotane after resection of adrenocortical carcinoma: A systematic review and meta-analysis. Biomed Res Int. 2018;2018:9362108. https:\/\/doi.org\/10.1155\/2018\/9362108.","journal-title":"Biomed Res Int"},{"issue":"10","key":"1249_CR13","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S2213-8587(23)00193-6","volume":"11","author":"M Terzolo","year":"2023","unstructured":"Terzolo M, et al. Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study. Lancet Diabetes Endocrinol. 2023;11(10):720\u201330. https:\/\/doi.org\/10.1016\/S2213-8587(23)00193-6.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"1249_CR14","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/s41416-021-01513-8","volume":"125","author":"O Kimpel","year":"2021","unstructured":"Kimpel O, et al. Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study. Br J Cancer. 2021;125(9):1233\u20138. https:\/\/doi.org\/10.1038\/s41416-021-01513-8.","journal-title":"Br J Cancer"},{"issue":"1","key":"1249_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.amjsurg.2020.10.038","volume":"222","author":"A Al Asadi","year":"2021","unstructured":"Al Asadi A, Hubbs DM, Sweigert PJ, Baker MS, Kabaker AS. Analysis of adjuvant chemotherapy in patients undergoing curative-intent resection of localized adrenocortical carcinoma. Am J Surg. 2021;222(1):119\u201325. https:\/\/doi.org\/10.1016\/j.amjsurg.2020.10.038.","journal-title":"Am J Surg."},{"key":"1249_CR16","unstructured":"Nelson AA, Woodard G. Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2,2-bis(parachlorophenyl)-1,1-dichloroethane (DDD or TDE). Arch Pathol (Chic). 1949;48(5):387\u201394. [Online]. Available: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18143915. Accessed 4\/8\/2024."},{"key":"1249_CR17","doi-asserted-by":"crossref","unstructured":"Lubitz JA, Freeman L, Okun R. Mitotane use in inoperable adrenal cortical carcinoma. JAMA. 1973;223(10):1109\u201312. [Online]. Available: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/4739370. Accessed 4\/8\/2024.","DOI":"10.1001\/jama.223.10.1109"},{"issue":"4","key":"1249_CR18","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1210\/jc.2017-02591","volume":"103","author":"F Megerle","year":"2018","unstructured":"Megerle F, et al. Mitotane monotherapy in patients with advanced adrenocortical carcinoma. J Clin Endocrinol Metab. 2018;103(4):1686\u201395. https:\/\/doi.org\/10.1210\/jc.2017-02591.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1249_CR19","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1210\/en.2015-2052","volume":"157","author":"CR LaPensee","year":"2016","unstructured":"LaPensee CR, Mann JE, Rainey WE, Crudo V, Hunt SW 3rd, Hammer GD. ATR-101, a selective and potent inhibitor of Acyl-CoA acyltransferase 1, induces apoptosis in H295R adrenocortical cells and in the adrenal cortex of dogs. Endocrinology. 2016;157(5):1775\u201388. https:\/\/doi.org\/10.1210\/en.2015-2052.","journal-title":"Endocrinology"},{"issue":"5","key":"1249_CR20","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s10637-020-00899-1","volume":"38","author":"DC Smith","year":"2020","unstructured":"Smith DC, et al. A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma. Invest New Drugs. 2020;38(5):1421\u20139. https:\/\/doi.org\/10.1007\/s10637-020-00899-1.","journal-title":"Invest New Drugs"},{"issue":"23","key":"1249_CR21","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","volume":"366","author":"M Fassnacht","year":"2012","unstructured":"Fassnacht M, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1200966.","journal-title":"N Engl J Med"},{"issue":"10","key":"1249_CR22","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/bjc.2013.229","volume":"108","author":"T Urup","year":"2013","unstructured":"Urup T, Pawlak WZ, Petersen PM, Pappot H, Rorth M, Daugaard G. Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study. Br J Cancer. 2013;108(10):1994\u20137. https:\/\/doi.org\/10.1038\/bjc.2013.229.","journal-title":"Br J Cancer"},{"issue":"2","key":"1249_CR23","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1677\/ERC-09-0281","volume":"17","author":"P Sperone","year":"2010","unstructured":"Sperone P, et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-\/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer. 2010;17(2):445\u201353. https:\/\/doi.org\/10.1677\/ERC-09-0281.","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"1249_CR24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1530\/EJE-09-0804","volume":"162","author":"S Wortmann","year":"2010","unstructured":"Wortmann S, et al. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol. 2010;162(2):349\u201356. https:\/\/doi.org\/10.1530\/EJE-09-0804.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1249_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s12672-016-0260-7","volume":"7","author":"M Kroiss","year":"2016","unstructured":"Kroiss M, et al. Salvage treatment of adrenocortical carcinoma with trofosfamide. Horm Cancer. 2016;7(3):211\u20138. https:\/\/doi.org\/10.1007\/s12672-016-0260-7.","journal-title":"Horm Cancer"},{"issue":"9","key":"1249_CR26","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1055\/a-0747-5571","volume":"127","author":"M Kroiss","year":"2019","unstructured":"Kroiss M, et al. Treatment of refractory adrenocortical carcinoma with thalidomide: Analysis of 27 patients from the european network for the study of adrenal tumours registry. Exp Clin Endocrinol Diabetes. 2019;127(9):578\u201384. https:\/\/doi.org\/10.1055\/a-0747-5571.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"6","key":"1249_CR27","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1530\/EJE-19-0570","volume":"181","author":"D Cosentini","year":"2019","unstructured":"Cosentini D, et al. Activity and safety of temozolomide in advanced adrenocortical carcinoma patients. Eur J Endocrinol. 2019;181(6):681\u20139. https:\/\/doi.org\/10.1530\/EJE-19-0570.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1249_CR28","doi-asserted-by":"publisher","first-page":"100422","DOI":"10.1016\/j.esmoop.2022.100422","volume":"7","author":"M Lagana","year":"2022","unstructured":"Lagana M, et al. Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma. ESMO Open. 2022;7(2):100422. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100422.","journal-title":"ESMO Open"},{"issue":"3","key":"1249_CR29","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3275\/8334","volume":"36","author":"A Ferrero","year":"2013","unstructured":"Ferrero A, et al. Metronomic chemotherapy may be active in heavily pre-treated patients with metastatic adreno-cortical carcinoma. J Endocrinol Invest. 2013;36(3):148\u201352. https:\/\/doi.org\/10.3275\/8334.","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"1249_CR30","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/cam4.449","volume":"4","author":"Y Liu-Chittenden","year":"2015","unstructured":"Liu-Chittenden Y, et al. Phase I trial of systemic intravenous infusion of interleukin-13-Pseudomonas exotoxin in patients with metastatic adrenocortical carcinoma. Cancer Med. 2015;4(7):1060\u20138. https:\/\/doi.org\/10.1002\/cam4.449.","journal-title":"Cancer Med"},{"issue":"1","key":"1249_CR31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s40425-018-0424-9","volume":"6","author":"C LeTourneau","year":"2018","unstructured":"LeTourneau C, et al. Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. J Immunother Cancer. 2018;6(1):111. https:\/\/doi.org\/10.1186\/s40425-018-0424-9.","journal-title":"J Immunother Cancer."},{"issue":"11","key":"1249_CR32","doi-asserted-by":"publisher","first-page":"e1655362","DOI":"10.1080\/2162402X.2019.1655362","volume":"8","author":"E Billon","year":"2019","unstructured":"Billon E, et al. PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma. Oncoimmunology. 2019;8(11):e1655362. https:\/\/doi.org\/10.1080\/2162402X.2019.1655362.","journal-title":"Oncoimmunology"},{"issue":"12","key":"1249_CR33","doi-asserted-by":"publisher","first-page":"6193","DOI":"10.1210\/jc.2019-00600","volume":"104","author":"BA Carneiro","year":"2019","unstructured":"Carneiro BA, et al. Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial. J Clin Endocrinol Metab. 2019;104(12):6193\u2013200. https:\/\/doi.org\/10.1210\/jc.2019-00600.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1249_CR34","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s40425-019-0722-x","volume":"7","author":"MA Habra","year":"2019","unstructured":"Habra MA, et al. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer. 2019;7(1):253. https:\/\/doi.org\/10.1186\/s40425-019-0722-x.","journal-title":"J Immunother Cancer."},{"issue":"1","key":"1249_CR35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1200\/JCO.19.01586","volume":"38","author":"N Raj","year":"2020","unstructured":"Raj N, et al. PD-1 Blockade in Advanced Adrenocortical Carcinoma. J Clin Oncol. 2020;38(1):71\u201380. https:\/\/doi.org\/10.1200\/JCO.19.01586.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1249_CR36","doi-asserted-by":"publisher","first-page":"1908771","DOI":"10.1080\/2162402X.2021.1908771","volume":"10","author":"O Klein","year":"2021","unstructured":"Klein O, et al. Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209\u2013538. Oncoimmunology. 2021;10(1):1908771. https:\/\/doi.org\/10.1080\/2162402X.2021.1908771.","journal-title":"Oncoimmunology."},{"issue":"6","key":"1249_CR37","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1055\/s-2004-814563","volume":"36","author":"C Fottner","year":"2004","unstructured":"Fottner C, Hoeflich A, Wolf E, Weber MM. Role of the insulin-like growth factor system in adrenocortical growth control and carcinogenesis. Horm Metab Res. 2004;36(6):397\u2013405. https:\/\/doi.org\/10.1055\/s-2004-814563.","journal-title":"Horm Metab Res"},{"issue":"1","key":"1249_CR38","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1210\/jc.2008-1456","volume":"94","author":"FM Barlaskar","year":"2009","unstructured":"Barlaskar FM, et al. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab. 2009;94(1):204\u201312. https:\/\/doi.org\/10.1210\/jc.2008-1456.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1249_CR39","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00280-009-1083-9","volume":"65","author":"P Haluska","year":"2010","unstructured":"Haluska P, et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol. 2010;65(4):765\u201373. https:\/\/doi.org\/10.1007\/s00280-009-1083-9.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"1249_CR40","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/bjc.2013.46","volume":"108","author":"A Naing","year":"2013","unstructured":"Naing A, et al. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer. 2013;108(4):826\u201330. https:\/\/doi.org\/10.1038\/bjc.2013.46.","journal-title":"Br J Cancer"},{"issue":"4","key":"1249_CR41","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s12672-014-0182-1","volume":"5","author":"AM Lerario","year":"2014","unstructured":"Lerario AM, et al. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent\/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. Horm Cancer. 2014;5(4):232\u20139. https:\/\/doi.org\/10.1007\/s12672-014-0182-1.","journal-title":"Horm Cancer"},{"issue":"4","key":"1249_CR42","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1158\/1078-0432.CCR-14-0303","volume":"21","author":"I Puzanov","year":"2015","unstructured":"Puzanov I, et al. A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. Clin Cancer Res. 2015;21(4):701\u201311. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0303.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1249_CR43","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","volume":"16","author":"M Fassnacht","year":"2015","unstructured":"Fassnacht M, et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015;16(4):426\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(15)70081-1.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1249_CR44","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1210\/jc.2012-1419","volume":"97","author":"M Kroiss","year":"2012","unstructured":"Kroiss M, et al. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab. 2012;97(10):3495\u2013503. https:\/\/doi.org\/10.1210\/jc.2012-1419.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1249_CR45","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1210\/jc.2013-2298","volume":"99","author":"C O'Sullivan","year":"2014","unstructured":"O\u2019Sullivan C, et al. The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer. J Clin Endocrinol Metab. 2014;99(4):1291\u20137. https:\/\/doi.org\/10.1210\/jc.2013-2298.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1249_CR46","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1210\/clinem\/dgz318","volume":"105","author":"M Kroiss","year":"2020","unstructured":"Kroiss M, et al. Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib. J Clin Endocrinol Metab. 2020;105(5):1461\u20138. https:\/\/doi.org\/10.1210\/clinem\/dgz318.","journal-title":"J Clin Endocrinol Metab"},{"key":"1249_CR47","unstructured":"Edgren M, Eriksson B, Wilander E, Westlin JE, Nilsson S, Oberg K. Biological characteristics of adrenocortical carcinoma: a study of p53, IGF, EGF-r, Ki-67 and PCNA in 17 adrenocortical carcinomas. Anticancer Res. 1997;17(2B):1303\u20139. [Online]. Available: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9137490. Accessed 4\/8\/2024."},{"issue":"6","key":"1249_CR48","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1210\/jc.2007-2564","volume":"93","author":"M Quinkler","year":"2008","unstructured":"Quinkler M, et al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab. 2008;93(6):2057\u201362. https:\/\/doi.org\/10.1210\/jc.2007-2564.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1249_CR49","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1530\/EJE-11-0918","volume":"166","author":"A Berruti","year":"2012","unstructured":"Berruti A, et al. Phase II study of weekly paclitaxel and sorafenib as second\/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol. 2012;166(3):451\u20138. https:\/\/doi.org\/10.1530\/EJE-11-0918.","journal-title":"Eur J Endocrinol"},{"key":"1249_CR50","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1186\/1471-2407-14-561","volume":"14","author":"DM Halperin","year":"2014","unstructured":"Halperin DM, Phan AT, Hoff AO, Aaron M, Yao JC, Hoff PM. A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers. BMC Cancer. 2014;14:561. https:\/\/doi.org\/10.1186\/1471-2407-14-561.","journal-title":"BMC Cancer."},{"issue":"2","key":"1249_CR51","doi-asserted-by":"publisher","first-page":"e001009","DOI":"10.1136\/jitc-2020-001009","volume":"8","author":"S Bedrose","year":"2020","unstructured":"Bedrose S, et al. Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma,\". J Immunother Cancer. 2020;8(2):e001009. https:\/\/doi.org\/10.1136\/jitc-2020-001009.","journal-title":"J Immunother Cancer."},{"issue":"3","key":"1249_CR52","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1210\/jc.2011-2765","volume":"97","author":"S Hahner","year":"2012","unstructured":"Hahner S, et al. [131I]iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma. J Clin Endocrinol Metab. 2012;97(3):914\u201322. https:\/\/doi.org\/10.1210\/jc.2011-2765.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1249_CR53","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1007\/BF03346721","volume":"34","author":"B Mariniello","year":"2011","unstructured":"Mariniello B, et al. Somatostatin receptor expression in adrenocortical tumors and effect of a new somatostatin analog SOM230 on hormone secretion in vitro and in ex vivo adrenal cells. J Endocrinol Invest. 2011;34(6):e131\u20138. https:\/\/doi.org\/10.1007\/BF03346721.","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"1249_CR54","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1210\/clinem\/dgz091","volume":"105","author":"S Grisanti","year":"2020","unstructured":"Grisanti S, et al. Treatment with 90Y\/177Lu-DOTATOC in patients with metastatic adrenocortical carcinoma expressing somatostatin receptors. J Clin Endocrinol Metab. 2020;105(3):e5. https:\/\/doi.org\/10.1210\/clinem\/dgz091.","journal-title":"J Clin Endocrinol Metab."}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-024-01249-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-024-01249-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-024-01249-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T04:31:03Z","timestamp":1723782663000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-024-01249-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,27]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1249"],"URL":"https:\/\/doi.org\/10.1007\/s11864-024-01249-6","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,27]]},"assertion":[{"value":"16 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}